1. HBW Insight
  2. >>Beauty
  3. >>Policy & Regulation
  4. >>Regulation

Consumers, Health Practitioners Heeded FDA’s Call For WEN-Related AEs

 
• By Lauren Nardella

FDA’s safety alert in July, asking WEN users and their doctors to share information regarding hair loss-related adverse events, yielded approximately 1,000 reports in just over two months, contributing to a massive increase in cosmetic AE reports for FY 2016.

FDA received close to a thousand adverse event reports associated with WEN products in the closing months of fiscal 2016 following a public appeal for information, which could prompt lawmakers and consumer advocates to ask why the agency waited to issue the call.

Hair loss-related complaints linked to WEN Cleansing Conditions trace back at least as far as 2010. Class actions...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation

FDA Urged To Issue Formaldehyde Rule As California Finds Non-Compliance With State Ban

 
• By Lauren Nardella

Stakeholders are still waiting for the US FDA to issue its widely anticipated proposed rule to prohibit formaldehyde and formaldehyde releasers from hair smoothing or straightening products.

Cloudy Tariff Conditions Expected To Linger In US

 
• By Malcolm Spicer

White House announces president extends deadline he set in April for other countries to make new tariff deals from July 9 to Aug. 1, when the administration will start sending letters warning other countries that higher tariffs could take effect.

US FDA’s Tough Talk On Talc: Regulating In An Echo Chamber

 
• By Michael McCaughan

An FDA “expert roundtable” on talc produced a new talking point on a potential drug safety risk, but the basis of that claim is difficult to determine.